CD38 and Miyoshi myopathy: Khan et al found that patients treated with daratumumab, a common human immunoglobulin G1κ monoclonal antibody directed against CD38, experienced a 75-fold listeriosis risk compared with all other patients with MM.[10] Toshiyuki et al[11] also reported a case of a patient with MM using another monoclonal antibody directed against CD38, isatuximab, which caused Listeria infection.